Donepezil: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
* Date of FDA Approval (Patent Expiration): 1996 (2008)<br /> | * Date of FDA Approval (Patent Expiration): 1996 (2008)<br /> | ||
* 2006 Sales: $1.4 Billion<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref> | * 2006 Sales: $1.4 Billion<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref> | ||
* Why You Should Care: One of the most effective treatments for the symptoms of [[Alzheimer's Disease]], although no definitive proof exists as to whether | * Why You Should Care: One of the most effective treatments for the symptoms of [[Alzheimer's Disease]], although no definitive proof exists as to whether it alters the progression of the disease. | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||